Analysis of serum CEA and CA199 in colorectal cancer patients with liver metastases

doi:10.3877/cma.j.issn.2095-3224.2015.04.12

Abstract

Abstract:

Objective

To discuss the relationship between serum CEA, CA199 distribution and clinical features in advanced colorectal cancer.

Methods

275 colorectal cancer patients were classified into groups according to gender, age, liver metastases, ascites, intestinal tumor diameter, intestinal tumor location, bloody stools, and hepatitis B. Retrospectively analyze the relationship between serum CEA, CA199 and those groups applying χ² and t-test.

Results

The mean serufm CEA, CA199 concentrations in CRC patients with liver metastasis, tumor in colon, bloody stools, ascites were significantly increased, and the difference was statistically significant(P<0.05), while there is no correlation with gender, age, intestinal tumor diameter, or hepatitis B(P>0.05).

Conclusions

Serum CEA, CA199 can be used as an early and effective diagnosis of colorectal cancer patients with liver metastases and should be widely used in clinical practice.

Key words: Colorectal neoplasms, Neoplasm metastasis, Liver, Biological markers

Fei-fei HUI, Kai LIU, Jia-he YANG. Analysis of serum CEA and CA199 in colorectal cancer patients with liver metastases[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2015, 04(04): 405-410.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2015.04.12

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2015/V04/I04/405

Figures/Tables 2

References 27

[1]	Siegel R, DeSantis C, Virgo K, et al.Cancer treatment and survivorship statistics.CA Cancer J Clin, 2012, 62(4): 220-241.
[2]	Siegel R, Naishadham D, Jemal A. Cancer statistics.CA Cancer J Clin, 2012, 62(1): 10-29.
[3]	Ferlay J, Soerjomataram I, Dikshit R, et al.Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012.Int J Cancer, 2015, 136(5): 359-386.
[4]	Vukobrat-Bijedic Z, Husic-Selimovic A, Bijedic N, et al.Sensitivity of symptomatology versus diagnostic procedures and concentration of CEA and CA19-9 in the early detection of colorectal cancer.Acta Inform Med, 2014, 22(2): 89-93.
[5]	Van Cutsem E, Nordlinger B, Adam R, et al.Towards a pan-European consensus on the treatment of patients with colorectal liver metastases.Eur J Cancer, 2006, 42(14): 2212-2221.
[6]	Muratore A, Zorzi D, Bouzari H, et alAsymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? .Ann Surg Oncol, 2007, 14(2): 766-770.
[7]	Ghossein RA, Rosai J. Polymerase chain reaction in the detection of micrometastases and circulating tumor cells.Cancer, 1996, 78(1): 10-16.
[8]	Gold P, Freedman SO.Demonstration of tumor-specific antigensin human colonic carcinomataby immunological tolerance and absorption techniques.J Exp Med, 1965, 121: 439-462.
[9]	Nollau P, Scheller H, Kona-Horstmann M, et al.Expression of CD66a(human C-CAM)and other members of the carcinoembryonic antigen gene family of adhesion molecules in human colorectal adenomas.Cancer Res, 1997, 57(12): 2354-2357.
[10]	Ordonez C, Zhai AB, Camacho-Leal P, et al.GPI-anchored CEA family glycoproteins CEA and CEACAM6 mediate their biological effects through enhanced integrin alpha5beta1-fibronectin interaction.J Cell Physiol, 2007, 210(3): 757-765.
[11]	Prager GW, Braemswig KH, Martel A, et al.Baseline carcinoembryonic antigen(CEA)serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer.Cancer Sci, 2014, 105(8): 996-1001.
[12]	Hostetter RB, Augustus LB, Mankarious R, et al.Carcinoembryonic antigen as a selective enhancer of colorectal cancer metastasis.J Natl Cancer Inst, 1990, 82(5): 380-385.
[13]	郭勇，刘杰，李醒亚．胃癌肝转移患者血清CEA、CA199分布及其临床意义．中国实用医刊，2012，39(19): 4-6.
[14]	Park YA, Lee KY, Kim NK, et al.Prognostic effect of perioperative change of serumcarcino-embryonic antigen level: a useful tool for detection of systemic recurrence in rectal cancer.Ann Surg Oncol, 2006, 13(5): 645-650.
[15]	Lin JK, Lin CC, Yang SH, et al.Early postoperative CEA level is a better prognostic indicator than is preoperative CEA level in predicting prognosis of patients with curable colorectal cancer.Int J Colorectal Dis, 2011, 26(9): 1135-1141.
[16]	高坚欣，祝文峰，马黛，等．卵巢良性畸胎瘤CA199异常升高一例报告．中外医疗，2009，29(31): 174.
[17]	Perkins GL, Slater ED, Sanders GK, et al.Serum tumor markers.Am Fam Physician, 2003, 68(6): 1075-1082.
[18]	Rao US, Hoerster NS, Thirumala S, et al.The influence of metastatic site on the expression of CEA and cellular localization of beta-catenin in colorectal cancer.J Gastroenterol Hepatol, 2013, 28(3): 505-512.
[19]	Zhong W, Yu Z, Zhan J, et al.Association of serum levels of CEA, CA199, CA125, CYFRA21-1 and CA72-4 and disease characteristics in colorectal cancer.Pathol Oncol Res, 2014.
[20]	荆结线，杜丽莉，王文达，等．结直肠癌患者血清肿瘤标志物水平与临床病理学特征的关系．中国肿瘤临床，2008，35(3): 162-166.
[21]	Zhang D, Yu M, Xu T, et al.Predictive value of serum CEA, CA19-9 and CA125 in diagnosis of colorectal liver metastasis in Chinese population.Hepatogastroenterology, 2013, 60(126): 1297-1301.
[22]	Petrioli R, Licchetta A, Roviello G, et al.CEA and CA19-9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab.Cancer Invest, 2012, 30(1): 65-71.
[23]	de Haas RJ, Wicherts DA, Flores E, et al.Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases.Ann Surg Oncol, 2010, 17(4): 1010-1023.
[24]	Tampellini M, Ottone A, Alabiso I, et al.The prognostic role of baseline CEA and CA19-9 values and their time-dependent variations in advanced colorectal cancer patients submitted to first-line therapy.Tumour Biol, 2014.
[25]	梁杏花．1092例原发性结直肠癌回顾性分析．广州：广州医学院消化内科，2012：1-24.
[26]	Utsunomiya T, Saitsu H, Saku M, et al.Rare occurrence of colorectal cancer metastasis in livers infected with hepatitis B or C virus.Am J Surg, 1999, 177(4): 279-281.
[27]	Verberne CJ, Nijboer CH, de Bock GH, et al.Evaluation of the use of decision-support software in carcino-embryonic antigen(CEA)-based follow-up of patients with colorectal cancer.BMC Med Inform Decis Mak, 2012, 12: 14.

临床特征		血清CEA均值	P值	CA199均值	P值
性别		?	?	?	?
?	男	73.34±195.091	0.711	164.31±265.66	0.519
?	女	65.54±130.724	0.711	144.26±234.93	0.519
年龄		?	?	?	?
?	<60岁	73.87±185.129	0.687	143.22±236.827	0.347
?	≥60岁	65.45±152.972	0.687	172.19±272.557	0.347
伴肝转移		?	?	?	?
?	否	20.6±93.649	0	69.36±155.45	0
?	是	106.81±203.923	0	220.28±290.363	0
肠瘤直径		?	?	?	?
?	<5 cm	74.99±186.799	0.583	180±287.236	0.067
?	≥5 cm	63.48±148.135	0.583	123.28±193.806	0.067
肠瘤位置		?	?	?	?
?	结肠	84.22±192.663	0.013	172.66±266.368	0.048
?	直肠	23.68±33.509	0.013	101.39±196.057	0.048
血便		?	?	?	?
?	否	83.4±191.267	0.031	179.8±268.954	0.009
?	是	32.74±85.539	0.031	89.17±188.487	0.009
腹水		?	?	?	?
?	无	53.85±131.725	0	141.31±237.269	0.024
?	有	157.97±294.564	0	235.74±317.841	0.024
乙肝		?	?	?	?
?	无	65.07±153.482	0.407	172.62±264.261	0.066
?	有	84.69±215.256	0.407	108.52±213.08	0.066

临床特征		血清CEA均值	P值	CA199均值	P值
性别		?	?	?	?
?	男	73.34±195.091	0.711	164.31±265.66	0.519
?	女	65.54±130.724	0.711	144.26±234.93	0.519
年龄		?	?	?	?
?	<60岁	73.87±185.129	0.687	143.22±236.827	0.347
?	≥60岁	65.45±152.972	0.687	172.19±272.557	0.347
伴肝转移		?	?	?	?
?	否	20.6±93.649	0	69.36±155.45	0
?	是	106.81±203.923	0	220.28±290.363	0
肠瘤直径		?	?	?	?
?	<5 cm	74.99±186.799	0.583	180±287.236	0.067
?	≥5 cm	63.48±148.135	0.583	123.28±193.806	0.067
肠瘤位置		?	?	?	?
?	结肠	84.22±192.663	0.013	172.66±266.368	0.048
?	直肠	23.68±33.509	0.013	101.39±196.057	0.048
血便		?	?	?	?
?	否	83.4±191.267	0.031	179.8±268.954	0.009
?	是	32.74±85.539	0.031	89.17±188.487	0.009
腹水		?	?	?	?
?	无	53.85±131.725	0	141.31±237.269	0.024
?	有	157.97±294.564	0	235.74±317.841	0.024
乙肝		?	?	?	?
?	无	65.07±153.482	0.407	172.62±264.261	0.066
?	有	84.69±215.256	0.407	108.52±213.08	0.066

?		血清CEA	P	血清CA199	P	联合检测	P
性别		?	?	?	?	?	?
?	男	54.90%(89/162)	0.991	47.50%(77/162)	0.918	66.70%(108/162)	0.919
?	女	54.90%(62/113)	0.991	46.90%(53/113)	0.918	67.30%(76/113)	0.919
年龄		?	?	?	?	?	?
?	<60岁	54.90%(84/153)	0.998	47.70%(73/153)	0.87	66.00%(101/153)	0.724
?	≥60岁	54.90%(67/122)	0.998	46.70%(57/122)	0.87	68.00%(83/122)	0.724
伴肝转移		?	?	?	?	?	?
?	无	26.50%(31/117)	0	26.60%(30/117)	0	39.30%(46/117)	0
?	有	75.90%(120/158)	0	63.30%(100/158)	0	87.30%(138/158)	0
肠瘤直径		?	?	?	?	?	?
?	<5cm	52.20%(83/159)	0.291	49.70%(79/159)	0.348	65.4%(104/159)	0.536
?	≥5cm	58.60%(68/116)	0.291	44.00%(51/116)	0.348	69.00%(80/116)	0.536
肠瘤位置		?	?	?	?	?	?
?	结肠	59.20%(125/211)	0.009	50.70%(107/211)	0.038	71.60%(151/211)	0.003
?	直肠	40.60%(26/64)	0.009	35.90%(23/64)	0.038	51.60%(33/64)	0.003
腹水		?	?	?	?	?	?
?	无	53.40%(124/232)	0.258	45.70%(106/232)	0.222	65.50%(152/232)	0.255
?	有	62.80%(27/43)	0.258	55.80%(24/43)	0.222	74.4%(32/43)	0.255
血便		?	?	?	?	?	?
?	无	62.10%(126/203)	0	51.70%(105/203)	0.013	74.90%(152/203)	0
?	有	34.70%(25/72)	0	34.70%(25/72)	0.013	44.40%(32/72)	0
乙肝		?	?	?	?	?	?
?	无	58.80%(120/204)	0.027	51.50%(105/204)	0.018	72.10%(147/204)	0.002
?	有	43.70%(31/71)	0.027	35.20%(25/71)	0.018	52.10%(37/71)	0.002

?		血清CEA	P	血清CA199	P	联合检测	P
性别		?	?	?	?	?	?
?	男	54.90%(89/162)	0.991	47.50%(77/162)	0.918	66.70%(108/162)	0.919
?	女	54.90%(62/113)	0.991	46.90%(53/113)	0.918	67.30%(76/113)	0.919
年龄		?	?	?	?	?	?
?	<60岁	54.90%(84/153)	0.998	47.70%(73/153)	0.87	66.00%(101/153)	0.724
?	≥60岁	54.90%(67/122)	0.998	46.70%(57/122)	0.87	68.00%(83/122)	0.724
伴肝转移		?	?	?	?	?	?
?	无	26.50%(31/117)	0	26.60%(30/117)	0	39.30%(46/117)	0
?	有	75.90%(120/158)	0	63.30%(100/158)	0	87.30%(138/158)	0
肠瘤直径		?	?	?	?	?	?
?	<5cm	52.20%(83/159)	0.291	49.70%(79/159)	0.348	65.4%(104/159)	0.536
?	≥5cm	58.60%(68/116)	0.291	44.00%(51/116)	0.348	69.00%(80/116)	0.536
肠瘤位置		?	?	?	?	?	?
?	结肠	59.20%(125/211)	0.009	50.70%(107/211)	0.038	71.60%(151/211)	0.003
?	直肠	40.60%(26/64)	0.009	35.90%(23/64)	0.038	51.60%(33/64)	0.003
腹水		?	?	?	?	?	?
?	无	53.40%(124/232)	0.258	45.70%(106/232)	0.222	65.50%(152/232)	0.255
?	有	62.80%(27/43)	0.258	55.80%(24/43)	0.222	74.4%(32/43)	0.255
血便		?	?	?	?	?	?
?	无	62.10%(126/203)	0	51.70%(105/203)	0.013	74.90%(152/203)	0
?	有	34.70%(25/72)	0	34.70%(25/72)	0.013	44.40%(32/72)	0
乙肝		?	?	?	?	?	?
?	无	58.80%(120/204)	0.027	51.50%(105/204)	0.018	72.10%(147/204)	0.002
?	有	43.70%(31/71)	0.027	35.20%(25/71)	0.018	52.10%(37/71)	0.002

Please choose a citation manager

Content to export